Panel discussion Ethics
Annelien Bredenoord is Professor of Ethics of Biomedical Innovation at the University Medical Center Utrecht, as well as member of the Senate of Dutch Parliament (D66). Her research group seeks to identify, evaluate and promote policies and practices that ensure that biomedical innovation (with a focus on regenerative medicine, biobanking, Big Data, genomics, reproductive technologies) develops in an ethically and socially responsible matter: how to translate biomedical innovations from basic research into clinical care and society in an ethically sound way?
Bredenoord co-authored over 70 articles and supervises several PhD students. She obtains funding from among others KWF (Dutch Cancer Society), NWO and ZonMw (among which a personal VENI grant).
Annelien is member of several (inter)national committees among which Chair of the Ethics Committee of the International Society for Stem Cell Research (ISSCR), the Young Academy (KNAW), the National Indication Committee Pre-implantation Genetic Diagnosis, the L’Oréal UNESCO: For Women in Science Award Committee, and UMC Utrecht’s Research Ethics Committee.
René Bernards’ laboratory at the Netherlands Cancer Institute uses functional genomic approaches to find vulnerabilities of cancers that can be exploited therapeutically. He founded Qameleon Therapeutics to repurpose abandoned and patent expired drugs for use in cancer. Qameleon aims to bring these drugs to patients at sustainable prices by working with investors who seek societal impact and generic drug makers.
Jacquelien is CEO of the Dutch CF Foundation (NCFS). This organization sets the CF research agenda in The Netherlands and abroad, with a research program that is patient driven. Her organization developed the concept of institutionalized patient participation. She is chairwoman of the Dutch CF-Registry and president of CF Europe. She is working on her PhD with the subject of institutionalized patients participation. Because of progress that is made in treatment of the disease, she is very much involved in personalized medicine, the technology of organoids and developments in health research.
Mark van Houdenhoven has been Chair of the Board of Directors (CEO) at the Sint Maartenskliniek since 2014, a specialized hospital for posture and movement. Since 2016, he is professor in Economic Management in Healthcare appointed at the Nijmegen School of Management at the Radboud University. Previously, he has held positions as a Board Member of the Haga Hospital in The Hague and the Beatrix hospital in Gorinchem, and various managerial positions for other healthcare organizations in the Netherlands. His academic background is focused on social security issues, public finance and healthcare.
Paul Korte is a pharmacist by education. After a short career in public and hospital pharmacies he switched to the pharmaceutical industry. Starting in clinical research he held various positions in marketing, both within the Netherlands and internationally. He returned to the Netherlands to work for Janssen, pharmaceutical companies of J&J, and became general manager in 2008. Being already active in various roles within the pharmaceutical industry association, he is currently chairman of the Board of Dutch Association for Innovative Medicines.